Active Ingredient History
Everolimus is a derivative of Rapamycin (sirolimus), it is a mTOR inhibitor that binds with high affinity to the FK506 binding protein-12 (FKBP-12), thereby forming a drug complex that inhibits the activation of mTOR. This inhibition reduces the activity of effectors downstream, which leads to a blockage in the progression of cells from G1 into S phase, and subsequently inducing cell growth arrest and apoptosis. Everolimus also inhibits the expression of hypoxia-inducible factor, leading to a decrease in the expression of vascular endothelial growth factor. The result of everolimus inhibition of mTOR is a reduction in cell proliferation, angiogenesis, and glucose uptake. Everolimus is indicated for the treatment of postmenopausal women with advanced hormone receptor-positive, HER2-negative breast cancer (advanced HR+ BC) in combination with exemestane, after failure of treatment with letrozole or anastrozole. Indicated for the treatment of adult patients with progressive neuroendocrine tumors of pancreatic origin (PNET) with unresectable, locally advanced or metastatic disease. Indicated for the treatment of adult patients with advanced renal cell carcinoma (RCC) after failure of treatment with sunitinib or sorafenib. Indicated for the treatment of adult patients with renal angiomyolipoma and tuberous sclerosis complex (TSC), not requiring immediate surgery. Indicated in pediatric and adult patients with tuberous sclerosis complex (TSC) for the treatment of subependymal giant cell astrocytoma (SEGA) that requires therapeutic intervention but cannot be curatively resected. Everolimus is marketed by Novartis under the tradenames Zortress (USA) and Certican (Europe and other countries) in transplantation medicine, and as Afinitor (general tumours) and Votubia (tumours as a result of TSC) in oncology. Everolimus is also available from Biocon, with the brand name Evertor, from Natco Pharma, with the brand name Temonat, from Ranbaxy Laboratories, with the brand name of Imozide, from Emcure Pharmaceuticals, with the brand name of Temcure, among over 20 different brands. NCATS
Drug Pricing (per unit)
Note: This drug pricing data is preliminary, incomplete, and may contain errors.
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
Breast Neoplasms (approved 2009)
Carcinoma, Renal Cell (approved 2009)
Neuroendocrine Tumors (approved 2009)
Acute Coronary Syndrome (Phase 4)
Adenocarcinoma (Phase 2)
Adenoma, Islet Cell (Phase 2)
Adrenal Cortex (Phase 2)
Allografts (Phase 4)
Anemia (Phase 1)
Angina Pectoris (Phase 4)
Angina, Stable (Phase 4)
Angiofibroma (Phase 2/Phase 3)
Angiolipoma (Phase 1/Phase 2)
Astrocytoma (Phase 3)
Autism Spectrum Disorder (Phase 2/Phase 3)
Autistic Disorder (Phase 2)
Bile Duct Neoplasms (Phase 2)
Birt-Hogg-Dube Syndrome (Phase 2)
BK Virus (Phase 4)
Brain Neoplasms (Phase 2)
Brain Stem Neoplasms (Phase 2)
Breast Diseases (Phase 2)
Breast Neoplasms (Phase 4)
Breast Neoplasms, Male (Phase 1/Phase 2)
Burkitt Lymphoma (Phase 1/Phase 2)
Carcinoid Tumor (Phase 3)
Carcinoma (Phase 3)
Carcinoma, Adenoid Cystic (Phase 2)
Carcinoma, Basal Cell (Phase 1)
Carcinoma, Hepatocellular (Phase 4)
Carcinoma, Islet Cell (Phase 2)
Carcinoma, Large Cell (Phase 4)
Carcinoma, Merkel Cell (Phase 1)
Carcinoma, Mucoepidermoid (Phase 1)
Carcinoma, Neuroendocrine (Phase 2)
Carcinoma, Non-Small-Cell Lung (Phase 2)
Carcinoma, Renal Cell (Phase 4)
Carcinoma, Squamous Cell (Phase 1)
Carcinoma, Transitional Cell (Phase 2)
Carcinoma, Verrucous (Phase 1)
Cholangiocarcinoma (Phase 2)
Chondrosarcoma (Phase 2)
Cognition Disorders (Phase 2/Phase 3)
Colonic Neoplasms (Phase 1/Phase 2)
Colorectal Neoplasms (Phase 2)
Comparative Study (Phase 4)
Coronary Artery Disease (Phase 4)
Coronary Disease (Phase 4)
Coronary Restenosis (Phase 4)
Coronary Stenosis (Phase 4)
COVID-19 (Phase 3)
Cytomegalovirus (Phase 4)
Cytomegalovirus Infections (Phase 4)
Delayed Graft Function (Phase 2/Phase 3)
Diabetes Mellitus, Type 1 (Phase 1/Phase 2)
Diffuse Intrinsic Pontine Glioma (Phase 2)
Drug Interactions (Phase 4)
Endocardial Cushion Defects (Phase 3)
Endometrial Hyperplasia (Phase 2)
Endometrial Neoplasms (Phase 2)
Ependymoma (Phase 2)
Epidermal Growth Factor (Phase 4)
Epilepsy (Phase 3)
ErbB Receptors (Phase 1)
Esophageal Neoplasms (Phase 3)
Everolimus (Phase 2/Phase 3)
Exercise (Phase 4)
Fallopian Tube Neoplasms (Phase 2)
Fibrosis (Phase 4)
Gallbladder Neoplasms (Phase 2)
Gastrinoma (Phase 2)
Gastrointestinal Diseases (Phase 4)
Gastrointestinal Neoplasms (Phase 2)
Gastrointestinal Stromal Tumors (Phase 1/Phase 2)
Geriatrics (Phase 4)
Glioblastoma (Phase 2)
Glioma (Phase 2)
Gliosarcoma (Phase 1)
Glucagonoma (Phase 2)
Graft Rejection (Phase 4)
Graft vs Host Disease (Phase 2/Phase 3)
Granuloma (Phase 1)
Growth and Development (Phase 4)
Hamartoma (Phase 2)
Hamartoma Syndrome, Multiple (Phase 1/Phase 2)
Head and Neck Neoplasms (Phase 2)
Heart Diseases (Phase 4)
Heart Failure (Phase 3)
Heart Transplantation (Phase 4)
Hematologic Diseases (Phase 1/Phase 2)
Hematopoietic Stem Cell Transplantation (Phase 2)
Hepatic Insufficiency (Phase 1)
Hepatitis C (Phase 4)
Hepatitis C, Chronic (Phase 2)
HIV (Phase 4)
Hodgkin Disease (Phase 2)
Hyperaldosteronism (Phase 2)
Hypertrophy, Left Ventricular (Phase 4)
Hypoglycemia (Phase 1/Phase 2)
Immunosuppression Therapy (Phase 4)
Immunosuppressive Agents (Phase 4)
Infections (Phase 4)
Insulinoma (Phase 2)
Intestinal Neoplasms (Phase 2)
Kidney Diseases (Phase 4)
Kidney Failure, Chronic (Phase 4)
Kidney Neoplasms (Phase 3)
Kidney Transplantation (Phase 4)
Leukemia (Phase 2)
Leukemia, Lymphocytic, Chronic, B-Cell (Phase 1/Phase 2)
Leukemia, Lymphoid (Phase 1/Phase 2)
Leukemia-Lymphoma, Adult T-Cell (Phase 1/Phase 2)
Leukemia, Myelogenous, Chronic, BCR-ABL Positive (Phase 1/Phase 2)
Leukemia, Myeloid, Acute (Phase 2)
Leukemia, Myeloid, Chronic-Phase (Phase 1)
Leukemia, Myelomonocytic, Chronic (Phase 1)
Livedoid Vasculopathy (Phase 4)
Liver Cirrhosis (Phase 2)
Liver Diseases (Phase 2)
Liver Failure (Phase 2)
Liver Neoplasms (Phase 2)
Liver Transplantation (Phase 4)
Living Donors (Phase 3)
Lung Diseases (Phase 3)
Lung Neoplasms (Phase 2)
Lung Transplantation (Phase 3)
Lymphangioleiomyomatosis (Phase 3)
Lymphoma (Phase 2)
Lymphoma, B-Cell (Phase 2)
Lymphoma, B-Cell, Marginal Zone (Phase 2)
Lymphoma, Follicular (Phase 1/Phase 2)
Lymphoma, Large B-Cell, Diffuse (Phase 3)
Lymphoma, Large-Cell, Anaplastic (Phase 1/Phase 2)
Lymphoma, Large-Cell, Immunoblastic (Phase 2)
Lymphoma, Mantle-Cell (Phase 2)
Lymphoma, Non-Hodgkin (Phase 1/Phase 2)
Lymphoma, T-Cell (Phase 1/Phase 2)
Lymphoma, T-Cell, Cutaneous (Phase 2)
Lymphoma, T-Cell, Peripheral (Phase 1/Phase 2)
Lymphoproliferative Disorders (Phase 2)
Macular Degeneration (Phase 2)
Malignant Carcinoid Syndrome (Phase 3)
Mastocytosis, Systemic (Phase 2)
Medulloblastoma (Phase 1)
Melanoma (Phase 2)
Meningioma (Phase 2)
Menopause (Phase 1)
Mesothelioma, Malignant (Phase 2)
mTOR Associated Protein, LST8 Homolog (Phase 2)
Mucositis (Phase 2)
Multiple Endocrine Neoplasia Type 1 (Phase 2)
Multiple Myeloma (Phase 2)
Muscle Strength (Phase 4)
Mutation (Phase 1/Phase 2)
Myelodysplastic Syndromes (Phase 2)
Myeloproliferative Disorders (Phase 1)
Myocardial Ischemia (Phase 4)
Nasopharyngeal Carcinoma (Phase 1)
Nasopharyngeal Neoplasms (Phase 1)
Neoplasm Metastasis (Phase 2)
Neoplasms (Phase 4)
Neoplasms, Germ Cell and Embryonal (Phase 2)
Neoplastic Processes (Phase 2)
Neuroblastoma (Phase 1)
Neuroendocrine Tumors (Phase 4)
Neurofibroma (Phase 2)
Neurofibroma, Plexiform (Phase 2)
Neurofibromatoses (Phase 2)
Neurofibromatosis 1 (Phase 2)
Neurofibromatosis 2 (Phase 2)
Neurofibrosarcoma (Phase 2)
Neuroma, Acoustic (Phase 2)
Oligodendroglioma (Phase 2)
Oncogene Proteins (Phase 1)
Oncogenes (Phase 1)
Organ Transplantation (Phase 4)
Oropharyngeal Neoplasms (Phase 1)
Osteosarcoma (Phase 2)
Ovarian Neoplasms (Phase 2)
Pancreatic Neoplasms (Phase 4)
Papilloma, Inverted (Phase 1)
Paraganglioma (Phase 1)
Paraganglioma, Extra-Adrenal (Phase 2)
Peutz-Jeghers Syndrome (Phase 2)
Pheochromocytoma (Phase 2)
Polycystic Kidney, Autosomal Dominant (Phase 4)
Polycystic Kidney Diseases (Phase 2/Phase 3)
Polyomavirus Infections (Phase 4)
Postmenopause (Phase 4)
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma (Phase 1/Phase 2)
Precursor Cell Lymphoblastic Leukemia-Lymphoma (Phase 1/Phase 2)
Primary Myelofibrosis (Phase 1/Phase 2)
Progeria (Phase 1/Phase 2)
Prostatic Neoplasms (Phase 3)
Renal Dialysis (Phase 4)
Renal Insufficiency (Phase 4)
Renal Insufficiency, Chronic (Phase 4)
Renal Replacement Therapy (Phase 4)
Respiratory Tract Infections (Phase 2)
Rhabdoid Tumor (Phase 1)
Rhabdomyosarcoma (Phase 1)
Saliva (Early Phase 1)
Salivary Gland Neoplasms (Phase 1)
Sarcoma (Phase 2)
Sarcoma, Kaposi (Phase 2)
Sarcoma, Synovial (Phase 1/Phase 2)
Sclerosis (Phase 3)
Self-Injurious Behavior (Phase 2)
Sezary Syndrome (Phase 1/Phase 2)
Skin Neoplasms (Phase 3)
Small Cell Lung Carcinoma (Phase 2)
Somatostatinoma (Phase 2)
Squamous Cell Carcinoma of Head and Neck (Phase 2)
Stomach Neoplasms (Phase 3)
Sturge-Weber Syndrome (Phase 2)
Testicular Neoplasms (Phase 2)
Thymoma (Phase 2)
Thyroid Neoplasms (Phase 2)
Tongue Neoplasms (Phase 1)
TOR Serine-Threonine Kinases (Phase 2)
Tracheal Diseases (Early Phase 1)
Transplantation (Phase 4)
Triple Negative Breast Neoplasms (Phase 2)
Tuberculosis (Phase 2)
Tuberous Sclerosis (Phase 3)
Ureteral Neoplasms (Phase 1)
Urinary Bladder Neoplasms (Phase 2)
Uterine Cervical Neoplasms (Phase 1)
Uterine Neoplasms (Phase 2/Phase 3)
Uveitis (Phase 2)
Vascular Diseases (Phase 4)
Vipoma (Phase 2)
Virus Diseases (Phase 4)
Waldenstrom Macroglobulinemia (Phase 2)
Xerostomia (Early Phase 1)
| Trial | Phase | Start Date | Organizations | Indications |
|---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue
